Current Studies

 

CURRENTLY ENROLLING STUDIES

 

 

 

 

 

Ages 60-85

Diagnostic PET Scan Trial

A phase II, Multicenter, screening study with flortaucipir F18 in patients with early symptomatic AD defined as prodromal AD and mild dementia due to AD. Subjects will have expressed preliminary interest in Lilly AD therapeutic trials similar to the LMDC trial (More Information) however consent for this trial does not constitute consent for any Lilly AD trial. Subjects will undergo vital signs, cognitive testing, ECG, and flortaucipir F18 scan. Screening may take place over sever days with all screening assessments performed within 30 days prior to flortaucipir injection

More Information

 

 

Ages 60-85

No Seasonal Transfers Allowed

A Phase II, Randomized, Double-Blind, Placebo-Controlled, study of LY3303560 in subjects with early symptomatic AD with low-to-medium cerebral tau burden. Subjects will undergo brain MRI, Tau (Flortaucipir F18) PET scan, cognitive testing, physical and neurological examinations. Study participation consists of a screening period up to 8 weeks, a 76-week infusion treatment period and a 4-week safety follow up period.

More Information

 

Ages 50-85

No Seasonal Transfers Allowed

A Phase II, Randomized, Double-Blind, Placebo-Controlled, study of LY3303560 in subjects with early symptomatic AD with low-to-medium cerebral tau burden. Subjects will undergo brain MRI, Tau (Flortaucipir F18) PET scan, cognitive testing, physical and neurological examinations. Study participation consists of a screening period up to 8 weeks, a 76-week infusion treatment period and a 4-week safety follow up period.

More Information

 

 

Ages 50-85

No Seasonal Transfers Allowed

A Phase II, Multi-center, Randomized, Double-Blind, Placebo-Group, Placebo-Controlled study to evaluate the safety and tolerability, efficacy, and PK of 60mg and 90mg AD-35 administered orally daily during 6 months of double-blind treatment followed by a second 6 months of open-label treatment to subjects with mild to moderate AD. Subjects will undergo cognitive testing, safety assessments, physical and neurological exams, brain MRI, and may consider optional participation involving lumbar puncture and additional lab work.

More Information

 

 

Ages 50-80

SEASONAL TRANSPORT ASSISTANCE AVAILABLE

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Efficacy of BIIB092 in Subjects with Mild Alzheimer’s Disease. Subjects will undergo brain MRI, Amyloid and Tau PET, cognitive testing, physical and neurological examinations, optional Lumbar Puncture. Study participation consists of a screening period of up to 9 weeks, a 76-week infusion treatment period, an End of Study visit, and follow up safety visit 14 weeks after last study dose treatment.

 More Information

 

 

Ages 50-90

 

A Phase 3, Multinational, Multicenter, Double-blind, Placebo-Controlled, Parallel-Group, Efficacy, Safety and Tolerability Study of BAN2401 in Patients with Early Alzheimer’s Disease. Subjects will undergo brain MRI, amyloid and tau PET, cognitive testing, physical and neurological examination. Study participation consists of an 18-month study in which 3 dose levels are given biweekly (once every 2 weeks) to separate groups of participants and 2 dose levels are given monthly (once every 4 weeks) to separate groups of participants. Participants will be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease dementia. Any participant who completes the study treatment (Visit 42 [Week 79] of the Core study) or discontinues the Core Study will be eligible to participate in the Extension Phase, provided they meet the Extension Phase inclusion and exclusion criteria. The Follow-up Visit in the Extension Phase will take place 3 months after the last dose of study drug.

 More Information

 

 

 

 

 

 

Neuropsychiatric Research Center of Southwest Florida, llc

An ERG Portfolio Company

14271 Metropolis Avenue, Suite A • Fort Myers, FL  33912